Comprehensive genetic analysis identifying novel genetic abnormalities responsible for myeloproliferative neoplasm
Project/Area Number |
23390255
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Kurume University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
OKU Eijiro 久留米大学, 医学部, 助教 (10569429)
MIZUNO Shinichi 九州大学, 先端医療イノベーションセンター, 准教授 (40569430)
|
Project Period (FY) |
2011-04-01 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥18,850,000 (Direct Cost: ¥14,500,000、Indirect Cost: ¥4,350,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2011: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
Keywords | 血液腫瘍学 / 遺伝子変異 / 造血器悪性腫瘍 / 染色体転座 / 癌 / ゲノム / 白血病 |
Research Abstract |
In this study, we performed a comprehensive genetic analysis by using a newly developed system for fusion-gene detection and whole exome analysis, in order to identify novel genetic abnormalities responsible for myeloproliferative neoplasm (MPN) and to develop a new therapeutic option. We could detect several candidate regions with altered genomic structures which would contribute to produce novel fusion-genes. In addition, many novel missense mutations were found in MPN cases by whole exome analysis, however, they are not shared among cases. We are applying CRISPR method to patients' derived iPSs in order to clarify genetic functions of those mutations. Furthermore, we found out that peptides derived from those mutations could be presented to patients' HLA molecules and be recognized by T cells. We are preparing a protocol to provide patients a novel therapeutic option as genetic analysis-based personalized immunotherapy.
|
Report
(4 results)
Research Products
(15 results)
-
[Journal Article] Donor-derived 47, XXY in an unrelated cord blood transplant recipient.2014
Author(s)
Kawaguchi K, Nakamura T, Nohara M, Koteda S, Nomura K, Morishige S, Oku E, Imamura R, Mouri F, Seki R, Osaki K, Hashiguchi M, Yoshimoto K, Nagafuji K, Okamura T.
-
Journal Title
Springerplus.
Volume: 6
Issue: 1
Pages: 72-72
DOI
Related Report
Peer Reviewed
-
[Journal Article] Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL : results of a prospective study (ALL MRD2002 Study)2013
Author(s)
Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G, Fujisaki T, Abe Y, Takamatsu Y, Yokota S, Akashi K, Harada M. (16名, 6番目)
-
Journal Title
J Hematol Oncol
Volume: 6
Issue: 1
Pages: 14-14
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] [Fatal zygomycosis caused by Mucor indicus after haplo-identical stem cell transplantation]2013
Author(s)
Koteda S, Nomura K, Hashiguchi M, Kawaguchi K, Oku E, Osaki K, Nakamura T, Mouri F, Imamura R, Seki R, Nagafuji K, Makimura K, Okamura T.
-
Journal Title
Rinsho Ketsueki.
Volume: 54(3)
Pages: 311-315
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-